Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in chronic inducible urticaria inadequately controlled by H1-antihistamines
2023-505739-12-01Phase 3Authorised
- Sponsor
- Novartis
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib in chronic inducible urticaria (CIndU), symptomatic dermatographism (SD), Cold urticaria (CU) and 1 more (3 arms), sponsored by Novartis. Planned start Sep 2024; status: authorised.
02
Drugs
remibrutinib
03
Conditions
chronic inducible urticaria (CIndU)symptomatic dermatographism (SD)Cold urticaria (CU)Cholinergic Urticaria (CU)
Beyond the preview
Go deeper on 2023-505739-12-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505739-12-01.